Literature DB >> 24410541

Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers.

Giuseppe Lippi1, Gianfranco Cervellin.   

Abstract

The prognostic significance of cardiospecific troponins and natriuretic peptides in patients with myocardial ischemia is well established, and their measurement is now endorsed by the most important guidelines and recommendations for diagnosis and management of heart failure (HF). Additional biomarkers have also been investigated to support clinical judgment and diagnostic imaging in the stratification of risk of cardiac dysfunction in patients with myocardial infarction (MI). We have performed a systematic analysis of the current scientific literature regarding the most important biomarkers of HF, selecting all prospective studies with adequate sample size (i.e. >100 patients) that have assessed, during the early phase of myocardial ischemia, the prognostic value of emergent biomarkers for new-onset HF or deterioration of cardiac function in patients with MI. This analysis has provided some good evidence suggesting that, in most cases, the use of diagnostic biomarkers of cardiac dysfunction does not translate into efficient risk prediction of HF. However, some notable exceptions were found, including biomarkers of cardiac fibrosis (especially galectin-3), growth differentiation factor-15 (GDF-15), osteoprotegerin, C-reactive protein (CRP), and red blood cell distribution width (RDW). Nevertheless, future studies with well-defined characteristics including the use of larger sample sizes, standardized end points, and replication populations, along with benchmark analyses against other consolidated biomarkers (i.e. cardiospecific troponins and natriuretic peptides), should be planned. Such evaluations will help to establish whether an integrated approach including biomarkers of different pathogenetic pathways - for example, apoptosis, stress of cardiomyocytes, cardiac fibrosis, inflammation, and extra-cardiac involvement - may be cost effective for identifying patients at increased risk of developing HF, and who, therefore, may benefit from a tailored therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24410541     DOI: 10.3109/10408363.2013.863267

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  15 in total

Review 1.  Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.

Authors:  Francisco Javier Carrasco-Sánchez; María Inmaculada Páez-Rubio
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

Review 2.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

Review 3.  Red blood cell distribution width and cardiovascular diseases.

Authors:  Elisa Danese; Giuseppe Lippi; Martina Montagnana
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

4.  Circulating Endothelial Cells and Endothelial Function Predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Magdy Abdel Hamid; Sameh W G Bakhoum; Yasser Sharaf; Dina Sabry; Ahmed T El-Gengehe; Ahmed Abdel-Latif
Journal:  J Interv Cardiol       Date:  2016-02       Impact factor: 2.279

Review 5.  HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.

Authors:  Rhoda Elison Hirsch; Nathawut Sibmooh; Suthat Fucharoen; Joel M Friedman
Journal:  Antioxid Redox Signal       Date:  2016-11-28       Impact factor: 8.401

6.  Red blood cell distribution width independently predicts medium-term mortality and major adverse cardiac events after an acute coronary syndrome.

Authors:  Gianni Turcato; Valentina Serafini; Alice Dilda; Chiara Bovo; Beatrice Caruso; Giorgio Ricci; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2016-07

Review 7.  Prognostic biomarkers in acute coronary syndrome.

Authors:  Gian Luca Salvagno; Chiara Pavan
Journal:  Ann Transl Med       Date:  2016-07

8.  Evaluation of red blood cell distribution width in dogs with various illnesses.

Authors:  Carlos Martinez; Carmel T Mooney; Robert E Shiel; Pak Kan Tang; Louise Mooney; Emma J O'Neill
Journal:  Can Vet J       Date:  2019-09       Impact factor: 1.008

9.  Diagnostic and Prognostic Properties of Osteoprotegerin in Patients with Acute Dyspnoea: Observations from the Akershus Cardiac Examination (ACE) 2 Study.

Authors:  Ragnhild Røysland; Mohammed Osman Pervez; Marit Holmefjord Pedersen; Jon Brynildsen; Arne Didrik Høiseth; Tor-Arne Hagve; Helge Røsjø; Torbjørn Omland
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

Review 10.  Red blood cell distribution width in heart failure: A narrative review.

Authors:  Giuseppe Lippi; Gianni Turcato; Gianfranco Cervellin; Fabian Sanchis-Gomar
Journal:  World J Cardiol       Date:  2018-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.